Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which eye test spots early glaucoma damage best?

NCT ID NCT06227611

Diagnosis Sponsor: Fondazione G.B. Bietti, IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

Researchers are testing three different visual field grids to see which one best detects central vision loss in people with early glaucoma and reduced retinal nerve thickness. The study compares the standard 10-2 and 24-2c tests with the G1 Octopus grid. About 16 glaucoma patients will take all three tests, and the team will measure how well the grids agree on spotting early damage. The goal is to find the most reliable way to catch central vision problems early, when treatment could help most.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
No drug or treatment is given. The study compares three visual field testing grids (10-2 HFA, 24-2c HFA, and G1 Octopus) used to detect central vision damage in glaucoma.
What this could lead to
If one grid proves more accurate, doctors could adopt it to catch early central vision loss in glaucoma sooner, helping preserve sight.
What could go wrong
The study is small and only compares test methods, not treatments. Results may not apply to all glaucoma patients, and the grids might agree closely, offering no clear winner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 16 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2021

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

glaucoma patients referring to glaucoma clinic of IRCCS-Fondazione GB Bietti and University of Rome Tor Vergata.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * glaucoma patients with glaucomatous optic nerve head defect and reduced ganglion cell layer thickness Exclusion Criteria: * age\<18 years * unable to read, understand and sign the written informed consent * unable to perform visual field test * advanced glaucoma with C/D\>0.7 * other causes of optic neuropathies * retinal or macular diseases * lens or corneal opacities * spherical refractive defect \>± 6D * cylindric refractive defect \>± 3D

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IRCCS-Fondazione GB Bietti

    RECRUITING

    Rome, Italy

  • University of Rome Tor Vergata

    RECRUITING

    Rome, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.